Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Mevidalen (LY3154207) in Healthy Subjects
NCT02365571Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mevidalen in Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Events at 48 hours. Started Feb 2015; status: completed.
02
Drugs
mevidalen
03
Conditions
Parkinson's disease dementia (PDD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT02365571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365571.